Femasys announced that it has completed the Stage 2 European Union (EU) Medical Device Regulation onsite audit resulting in zero nonconformances and no findings. This is the final audit phase in the MDR designation process that was conducted by TUV SUD America Inc., a recognized Auditing Organization and Notified Body. Successful completion of both Stage 1 and Stage 2 MDR audits confirms Femasys is compliant in all areas of MDR and may progress to issuance of the MDR certification, allowing for Femasys’ products to secure CE Marking.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FEMY:
- Femasys Inc. EU MDR Final Audit Successfully Completed
- Femasys to showcase FemBloc, other products at AAGL meeting
- Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
- Femasys regains compliance with Nasdaq listing requirements
- Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue